CIP Treatment Knowledge & Referral 3 — Questions and Answers
Question 1: Which treatment modality is most strongly supported by evidence for treating both substance use disorders and co-occurring anxiety?
- Hypnotherapy
- Cognitive Behavioral Therapy (CBT) (Correct answer)
- Equine-assisted therapy alone
- Confrontational group therapy
Correct answer: Cognitive Behavioral Therapy (CBT)
CBT has the strongest evidence base for treating substance use disorders and anxiety, targeting maladaptive thought patterns and behaviors simultaneously.
Question 2: When referring a client to a methadone clinic, which federal regulation governs the dispensing of methadone for OUD treatment?
- DEA Schedule II only regulations
- SAMHSA's Opioid Treatment Program (OTP) regulations under 42 CFR Part 8 (Correct answer)
- State pharmacy board rules exclusively
- The Mental Health Parity Act
Correct answer: SAMHSA's Opioid Treatment Program (OTP) regulations under 42 CFR Part 8
Methadone for OUD must be dispensed through SAMHSA-certified Opioid Treatment Programs regulated under 42 CFR Part 8.
Question 3: A sober living home (SLH) is best described as what type of treatment resource?
- A licensed medical detox facility
- A peer-supported, abstinence-based recovery residence with minimal clinical services (Correct answer)
- An intensive outpatient program with housing
- A psychiatric step-down unit
Correct answer: A peer-supported, abstinence-based recovery residence with minimal clinical services
Sober living homes provide structured, abstinence-based peer housing that supports ongoing recovery without formal clinical treatment services.
Question 4: Which factor is LEAST relevant when matching a client to a specific treatment program?
- The client's primary substance and severity of use
- The geographic proximity to the client's drug dealer (Correct answer)
- The availability of gender-specific programming
- The client's history of prior treatment attempts
Correct answer: The geographic proximity to the client's drug dealer
Proximity to a drug dealer is a contraindication for local treatment but not a treatment-matching factor — the other options directly inform clinical placement decisions.
Question 5: In the context of referral, what does 'continuity of care' mean?
- The client remains in the same facility indefinitely
- Seamless transition between levels of care as the client's needs change (Correct answer)
- Family members receive identical services to the client
- Insurance coverage stays constant throughout treatment
Correct answer: Seamless transition between levels of care as the client's needs change
Continuity of care ensures clients transition smoothly from detox to residential to outpatient to aftercare as their clinical needs evolve.
Question 6: What is the role of a Patient Placement Criteria (PPC) tool such as the ASAM Criteria in the referral process?
- It determines the client's insurance deductible
- It provides a standardized, multidimensional framework for matching clients to appropriate care levels (Correct answer)
- It replaces the need for a clinical assessment
- It documents the intervention script
Correct answer: It provides a standardized, multidimensional framework for matching clients to appropriate care levels
The ASAM Criteria use six multidimensional assessment areas to guide placement decisions across the continuum of care in a standardized way.
Question 7: A client is step-down from residential treatment and still needs structured services but can sleep at home. Which level of care is appropriate?
- ASAM Level 4.0 Medically Managed Inpatient
- ASAM Level 2.1 Intensive Outpatient Program (IOP) (Correct answer)
- ASAM Level 0.5 Early Intervention
- ASAM Level 3.7 Medically Monitored Inpatient
Correct answer: ASAM Level 2.1 Intensive Outpatient Program (IOP)
ASAM Level 2.1 IOP provides 9+ hours of structured weekly services while allowing the client to live at home, making it appropriate post-residential step-down.
CIP Treatment Knowledge & Referral 3
Which treatment modality is most strongly supported by evidence for treating both substance use disorders and co-occurring anxiety?